Kitron ASA
Kitron: Allocation of options
Kitron: Allocation of options
(2025-10-23) On 23 October 2025, the board of directors of Kitron ASA (the "Company" or "Kitron") resolved to issue 1 600 000 options under Kitron's long-term incentive program for the period 2024 – 2030.
The options are issued with 800 000 options each to Subprogram A (2024 – 2027) and Subprogram B (2025 – 2028), and in accordance with the board of directors' guidelines for remuneration of senior executives as approved by Kitron's annual general meeting held 25 April 2025. The share option program and properties of the options are a continuation of Kitron's share option program as described in note 19 in Kitron's annual financial statements for 2024.
A total of 1 030 000 options is allocated to primary insiders as further set out in the attached primary insider notifications pursuant to the market abuse regulation article 19.
For further information, please contact:
Tuomo Lähdesmäki, Chairman of the Board of Kitron
Tel.: +358-50-5879648
E-mail: investorrelations@kitron.com
About Kitron
Kitron is a leading Scandinavian electronics manufacturing services company for the Connectivity, Electrification, Industry, Medical devices and Defence/Aerospace sectors. The group has operations located in Norway, Sweden, Denmark, Lithuania, Germany, Poland, the Czech Republic, India, Malaysia, China and the United States. Kitron has about 2 400 employees, and revenues were EUR 647 million in 2024.
www.kitron.com (http://www.kitron.com)
This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and section 5-12 of the Norwegian Securities Trading Act.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Allwyn23.10.2025 21:00:00 CEST | Press release
The John Langdon Down Foundation Wins F1® Allwyn Global Community Award at Mexico Grand Prix
Zymeworks Inc.23.10.2025 18:30:00 CEST | Press release
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Sword Group23.10.2025 18:25:00 CEST | Press release
Sword Group: Acquisition of Full On Net, strengthening its expertise in data science and digital platforms
Sword Group23.10.2025 18:00:00 CEST | Press release
Sword Group: Q3 2025 Results
Hiab Corporation23.10.2025 17:45:00 CEST | Press release
Hiab's financial information in 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom